What the studies show
Obese rhesus monkeys lost weight rapidly and improved insulin resistance, with imaging confirming loss of white fat — the result the product is sold on. Grade D because it is not human evidence.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.Sci Transl Med, 2011Rhesus and other monkeys; preclinical; reversible kidney toxicity reported.
In context
Adipotide is a two-part synthetic peptide: a homing sequence that binds a protein on the blood vessels of white fat, joined to a fragment that triggers cell death. Cut off the blood supply and the fat tissue shrinks. In obese monkeys it produced rapid weight loss and better insulin sensitivity — and dose-dependent, reversible kidney damage. A human phase 1 trial in prostate cancer was registered in 2010 and no result was ever published. It is sold online as a fat-loss peptide on the strength of the monkey study. It is not approved anywhere and is prohibited in sport.
Adipotide is not approved; investigational (stalled). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Adipotide proven to help with fat loss?
What studies are behind the grade?
Is Adipotide approved for this?
Other outcomes for Adipotide
- DFat loss (humans)0 published
- DKidney toxicity (primates)adversePreclinical only
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →